Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

André, Thierry; de Gramont, Armand; Vernerey, Déwi; Chibaudel, Benoist; Bonnetain, Franck; Tijeras‐Raballand, Annemilaï; Scriva, Aurélie; Hickish, Tamas; Tabernero, Josep; Van Laethem, Jean‐Luc; Banzi, Maria; Maartense, E.; Shmueli, Einat; Carlsson, Göran; Scheithauer, Werner; Papamichael, Demetris; Moehler, M.; Landolfi, Stefania; Demetter, Pieter; Colote, Soudhir; Tournigand, Christophe; Louvet, Christophe; Duval, Alex; Fléjou, Jean-François; de Gramont, Aimery

doi:10.1200/jco.2015.63.4238

Public

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Published in Journal of Clinical Oncology • Nov 2, 2015

Authors:

Thierry André

Armand de Gramont

Déwi Vernerey

Abstract

PURPOSE: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. ...

Subject

Medicine

Oxaliplatin

Fluorouracil

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!